|
Market Closed -
Nasdaq
01:30:00 24/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.5193 USD | -7.84% |
|
+6.37% | -67.13% |
| 12/10 | Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. | CI |
| 09/10 | Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer | MT |
Company Valuation: Outlook Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 126.4 | - | - |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 168.5% | - | - |
| Enterprise Value (EV) | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 126.4 | 126.4 | 126.4 |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 168.5% | 0% | 0% |
| P/E | -6.2x | -3.94x | -0.92x | -1.32x | -0.59x | -0.9x | -2.4x | 5.77x |
| PBR | 71.9x | 29.6x | - | - | - | - | - | - |
| PEG | - | 0.3x | 0x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | 33.3x | 185x | 2.87x | 0.74x |
| EV / Revenue | - | - | - | - | 0x | 185x | 2.87x | 0.74x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.38x | -3.7x | 1.58x |
| EV / FCF | - | -0x | -0x | - | - | -3.24x | -11.5x | 0.94x |
| FCF Yield | - | -20.5% | -74.7% | - | - | -30.8% | -8.7% | 107% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7 | -6.2 | -4.8 | -4.06 | -1.79 | -0.58 | -0.2167 | 0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 1.413 | 0.6827 | 44.07 | 170.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.73 | -63.07 | -53.13 | -71.7 | -67.06 | -53.11 | -34.16 | 80.01 |
| Net income 1 | -53.16 | -66.05 | -58.98 | -75.37 | -62.42 | -65.1 | -44.43 | 20.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 43.4000 | 24.4000 | 4.4200 | 5.3400 | 1.0600 | 0.5193 | 0.5193 | 0.5193 |
| Nbr of stocks (in thousands) | 8,767 | 11,307 | 13,012 | 23,656 | 44,420 | 2,43,448 | - | - |
| Announcement Date | 22/12/21 | 29/12/22 | 22/12/23 | 27/12/24 | 19/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.9x | - | - | - | 13Cr | |
| 18.83x | 6.63x | 13.18x | 1.58% | 6.47TCr | |
| 30.16x | 8x | 26.2x | 0.05% | 5.48TCr | |
| 36.79x | 6.53x | 19.51x | 0.88% | 5.35TCr | |
| 35.59x | 3.45x | 14.87x | -.--% | 4.6TCr | |
| 49.71x | 5.74x | 31.52x | -.--% | 4.29TCr | |
| -19.41x | 187.75x | -20.66x | -.--% | 4.01TCr | |
| 28.93x | 8.21x | 21.27x | 0.37% | 3.35TCr | |
| 27.67x | 5.83x | 15.12x | -.--% | 2.4TCr | |
| 32.66x | 5.97x | 20.09x | -.--% | 2.37TCr | |
| Average | 24.00x | 26.46x | 15.68x | 0.32% | 3.83TCr | |
| Weighted average by Cap. | 26.71x | 25.33x | 15.90x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OTLK Stock
- Valuation Outlook Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
